Classified under consulting services, the company recorded no revenue from operations in FY26 and Q1 FY27. Total income for FY26 was Rs 3.14 lakhs, derived entirely from other income, against total expenses of Rs 12.99 lakhs, leaving a net loss of Rs 10.87 lakhs versus a Rs 3.73 lakh profit in FY25. Employee costs rose to Rs 4.15 lakhs from Rs 2.80 lakhs, and other expenses stood at Rs 8.83 lakhs. The company sold its entire 48,000-share holding in INOR Medical Products Limited to Nowrosjee Wadia and Sons Limited in February 2026, generating Rs 178.52 lakhs of other comprehensive income that lifted cash and cash equivalents from Rs 2 lakhs to Rs 202.95 lakhs. The board still recommended a final dividend of Rs 87 per share on a Rs 10 face value, for shareholder approval at the 44th AGM in June 2026. The company has no subsidiaries and only 27 shareholders on the record date. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Revenue from operations (consulting services), Other income. Dormant or near-dormant listed entity with no operating revenue.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| EBITDA (ex other income) | (0) | (0) | (0) | 0 | (0) |
| margin % | — | — | — | 4.1 | — |
| Owners' profit | (0) | (0) | (0) | 0 | (0) |
| EPS, as reported (₹) | (2.69) | (2.51) | (5.96) | 1.87 | 5.44 |
| ROE % · ROCE % | (7.2) · (6.9) | (7.2) · (7.2) | (20.6) · (20.6) | 6.0 · 6.0 | (5.1) · (4.7) |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from operations | (0) | (0) | (0) | (0) | (0) |
| Capex | 0 | 0 | 0 | 0 | 0 |
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | (0) | (0) | (0) | 0 | (0) | (0) | (0) | (0) |
| Net profit | (0) | (0) | (0) | 0 | (0) | (0) | (0) | (0) |
| EPS (₹) | (2.30) | (1.27) | (0.75) | 5.03 | 0.99 | 1.15 | 1.24 | 2.06 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| CENTRAL MINE P N D INST L | 15,301 | 50.3 | 6.70 | — | 26.9 | 34.6 | — | 34.9 |
| IIRM HOLDINGS INDIA LIMITED | 966 | 39.4 | 6.13 | 16.3 | 15.5 | 14.4 | — | 24.9 |
| Qualitek Labs Limited | 647 | 41.5 | — | — | — | 8.5 | — | — |
| Monarch Surveyors and Engineer | 411 | 8.4 | — | — | — | 20.9 | — | — |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 11 Sept 2026 · New Director appointed, CFO and Company Secretary resign | management changes | medium | — | — |
| 11 Sept 2026 · Director appointed, CS and CFO resigns at Technojet Consultants | management changes | medium | — | — |
| 11 Sept 2026 · Board approves new Company Secretary and director; CFO and CS Ojha resigns | management changes | medium | — | — |
| 11 Sept 2026 · CFO and Company Secretary resign; new Director and CS appointed | management changes | high | — | — |
| 11 Sept 2026 · CS and CFO resigns; new Director and Company Secretary appointed | management changes | high | — | — |
| 11 Sept 2026 · CFO and Company Secretary resigns; new Director and CS appointed | management changes | medium | — | — |
| 22 Aug 2026 · Re-appointment of Independent Director Nitin Datanwala for 5 years | management changes | medium | — | — |
| 21 Aug 2026 · Independent Director Nitin Datanwala reappointed for a second five-year term | management changes | medium | — | — |
| 29 Jul 2026 · Reminder to physical shareholders to update PAN, KYC and nomination details | compliance | minimal | — | — |
| 17 Jul 2026 · Newspaper Publication of Quarterly Results for June 2026 | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| Ekansh Concepts Limited |
| 308 |
| 46.9 |
| 6.78 |
| 182.6 |
| (6.7) |
| (6.8) |
| (12.2) |
| 48.8 |
| LIKHAMI CONSULTING LIMITED | 297 | 934.1 | 8.46 | — | 0.7 | 0.9 | — | 67.2 |
| EKI ENERGY SERVICES LTD | 189 | 11.0 | 0.49 | 19.1 | (4.3) | (3.0) | — | (6.1) |
| MITCON CON & ENG SER LTD | 139 | 12.7 | 0.81 | 6.7 | 5.4 | 5.1 | — | 12.7 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 18.3 | 8.4 | 18 of 25 | 29% |
| P/B | 0.9 | 1.8 | 6 of 17 | 69% |
| ROCE | (4.7) | 7.9 | 25 of 27 | 8% |
| ROE | (5.1) | 5.8 | 17 of 20 | 16% |
| Debt / Equity | 0.0 | 0.0 | 4 of 20 | 53% |
| Revenue growth | (100.0) | 10.3 | 18 of 18 | 0% |
| Profit growth | (140.9) | (29.8) | 16 of 18 | 12% |
| Market cap | 2 | 37 | 26 of 26 | 0% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
